U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H19Cl2NO2
Molecular Weight 304.2126
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORAMBUCIL

SMILES

C(Cc1ccc(cc1)N(CCCl)CCCl)CC(=O)O

InChI

InChIKey=JCKYGMPEJWAADB-UHFFFAOYSA-N
InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)

HIDE SMILES / InChI
Chlorambucil is a bifunctional 12 alkylating agent of the nitrogen mustard type that has been found active against selected human 13 neoplastic diseases. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA. Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. There are no known drug/drug interactions with chlorambucil.

CNS Activity

Curator's Comment:: Data in rats only. Chlorambucil is ionized at physiological pH and thus minimally enters brain, with a brain/plasma concentration of only 0.02.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

-4.036608E11
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

-4.036608E11
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

-4.036608E11
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

-4.036608E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.46 μg/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
259 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.99 μg × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
380 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.94 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
CHLORAMBUCIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Disc. AE: Irritability, Myoclonic jerks...
AEs leading to
discontinuation/dose reduction:
Irritability
Myoclonic jerks
Exaggerated startle response
Vomiting
Bone marrow depression (mild)
Abnormal EEG
Sources:
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Disc. AE: Convulsive seizure, Comatose...
AEs leading to
discontinuation/dose reduction:
Convulsive seizure
Comatose
Vomiting
Sources: Page: p.239
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Co-administed with::
cimetidine, p.o(600 mg; single)
aspirin
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: M
Population Size: 1
Sources:
Disc. AE: Acute renal failure, Seizures...
AEs leading to
discontinuation/dose reduction:
Acute renal failure
Seizures
Sources:
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Disc. AE: Bone marrow depression, Carcinogenicity...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Carcinogenicity
Infertility
Sources: Page: p.1
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Disc. AE: Convulsions, Metastases...
AEs leading to
discontinuation/dose reduction:
Convulsions
Metastases
Leukemia
Sources: Page: p.2
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Disc. AE: Skin rash, Erythema multiforme...
AEs leading to
discontinuation/dose reduction:
Skin rash (rare)
Erythema multiforme (rare)
Toxic epidermal necrolysis (rare)
Stevens-Johnson syndrome (rare)
Sources: Page: p.3
AEs

AEs

AESignificanceDosePopulation
Abnormal EEG Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Exaggerated startle response Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Irritability Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Myoclonic jerks Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Vomiting Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Bone marrow depression mild
Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Comatose Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Convulsive seizure Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Vomiting Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Acute renal failure Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Co-administed with::
cimetidine, p.o(600 mg; single)
aspirin
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: M
Population Size: 1
Sources:
Seizures Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Co-administed with::
cimetidine, p.o(600 mg; single)
aspirin
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: M
Population Size: 1
Sources:
Bone marrow depression Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Carcinogenicity Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Infertility Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Convulsions Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Leukemia Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Metastases Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Erythema multiforme rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Skin rash rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Stevens-Johnson syndrome rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Toxic epidermal necrolysis rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
PubMed

PubMed

TitleDatePubMed
Non-corticosteroid treatment for nephrotic syndrome in children.
2001
Treatment of membranous nephropathy.
2001
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
2001
Potential new therapeutic options in Behçet's syndrome.
2001
[Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents].
2001
Severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese.
2001
Esters of chlorambucil with 2-substituted 1,4-dihydroxy-9,10-anthraquinones as multifunctional anticancer agents.
2001 Apr
Treatment of Behçet's disease--an update.
2001 Apr
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
2001 Aug 15
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
2001 Dec
Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.
2001 Dec
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
2001 Dec
Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
2001 Dec
[Acute cholestatic hepatitis due to chlorambucil].
2001 Feb
Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells.
2001 Jul
Cutaneous xanthomas with concurrent demodicosis and dermatophytosis in a cat.
2001 Jul
Genetic damage by bifunctional agents in repair-active pre-meiotic stages of Drosophila males.
2001 Jul 1
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
2001 Jul 6
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
2001 Jun
Chlorambucil/prednisone-induced seizures in a patient with non-Hodgkin's lymphoma.
2001 Jun
The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics.
2001 Jun 15
[Chronic lymphocytic leukemia. 2. Therapy].
2001 Jun 8
Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment.
2001 Mar
Idiopathic erythrocytosis, diagnosis and clinical management.
2001 Mar
Hypercalcaemia associated with chronic lymphocytic leukaemia in a Giant Schnauzer.
2001 May
[Paraneoplastic pemphigus: a pustular form during chronic lymphoid leukemia].
2001 May
Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide.
2001 May
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
2001 May 18
[Pneumonia in patients with chronic lymphocytic leukemia. Study of 30 episodes].
2001 May 26
2-[N1-2-pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: a potent antitumor agent.
2001 May 7
Giant cell arteritis and renal amyloidosis: report of a case.
2001 Nov
Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
2001 Nov
Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome.
2001 Nov
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype.
2001 Nov
Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation.
2001 Nov 1
A novel kind of antitumour drugs using sulfonamide as parent compound.
2001 Nov-Dec
Sequence-specific DNA cleavage by dipeptides disubstituted with chlorambucil and 2,6-dimethoxyhydroquinone-3-mercaptoacetic acid.
2001 Nov-Dec
Characteristic and controlled release of anticancer drug loaded poly (D,L-lactide) microparticles prepared by spray drying technique.
2001 Nov-Dec
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
2001 Sep
[Vascular purpura in a patient with severe sarcoptic acariasis].
2001 Sep
Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells.
2001 Sep
A case of Behćet's disease complicated by visceral Leishmaniasis and myelodysplasia: clinical considerations.
2001 Sep
Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
2001 Sep 1
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.
2001 Sep 20
Chronic lymphocytic leukaemia.
2001 Sep-Oct
Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
2002 Jan
Sciatica or spinal lymphoma.
2002 Jan
A 6-bp deletion in the Crygc gene leading to a nuclear and radial cataract in the mouse.
2002 Jan
Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience.
2002 Jan
Developments in the treatment of uveitis.
2002 Jan
Patents

Sample Use Guides

0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Chronic lymphocytic leukaemia cells were treated
The inhibition of 3H-thymidine incorporation into the DNA of mitogen-stimulated lymphocytes from patients with chronic lymphocytic leukaemia by chlorambucil was measured in vitro. For the lymphocytes from the untreated patients the mean ID50 was 3.1 ug/ml.
Name Type Language
CHLORAMBUCIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
CB-1348
Code English
CHLORAMBUCIL [JAN]
Common Name English
CHLORAMBUCIL [WHO-DD]
Common Name English
CHLORAMBUCIL [EP MONOGRAPH]
Common Name English
CHLORAMBUCIL [IARC]
Common Name English
4-(P-(BIS(2-CHLOROETHYL)AMINO)PHENYL)BUTYRIC ACID
Common Name English
CHLORAMBUCILUM [WHO-IP LATIN]
Common Name English
AMBOCHLORIN
Common Name English
LEUKERAN
Brand Name English
NSC-3088
Code English
CHLORAMBUCIL [VANDF]
Common Name English
ECLORIL
Common Name English
BENZENEBUTANOIC ACID, 4-(BIS(2-CHLOROETHYL)AMINO)-
Common Name English
LYMPHOLYSIN
Common Name English
CHLORAMBUCIL [MART.]
Common Name English
CHLORAMBUCIL [HSDB]
Common Name English
CHLORAMBUCIL [WHO-IP]
Common Name English
NCI-3088
Code English
CHLORAMBUCIL [USP-RS]
Common Name English
CHLORAMBUCIL [INN]
Common Name English
CHLORAMBUCIL [ORANGE BOOK]
Common Name English
CHLORAMBUCIL [MI]
Common Name English
CHLORAMBUCIL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
LIVERTOX 189
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
NDF-RT N0000175558
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
NDF-RT N0000000236
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
NCI_THESAURUS C697
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
WHO-VATC QL01AA02
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
WHO-ATC L01AA02
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
Code System Code Type Description
WIKIPEDIA
CHLORAMBUCIL
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
EVMPD
SUB06172MIG
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
USP_CATALOG
1106001
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY USP-RS
CAS
305-03-3
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
MERCK INDEX
M3343
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY Merck Index
EPA CompTox
305-03-3
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-162-0
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
IUPHAR
7143
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
ChEMBL
CHEMBL515
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
HSDB
3026
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
FDA UNII
18D0SL7309
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
DRUG BANK
DB00291
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
RXCUI
2346
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY RxNorm
PUBCHEM
2708
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
INN
603
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
NCI_THESAURUS
C362
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
MESH
D002699
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
DRUG CENTRAL
588
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CHLORAMBUCIL
Created by admin on Fri Jun 25 20:54:56 UTC 2021 , Edited by admin on Fri Jun 25 20:54:56 UTC 2021
PRIMARY Description: A white or almost white, crystalline or slightly granular powder. Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R. Category: Cytotoxic drug. Storage: Chlorambucil should be kept in a well-closed container, protected from light. Additional information: CAUTION: Chlorambucil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Chlorambucil contains not less than 98.0% and not more than 101.0% of C14H19Cl2NO2, calculated with reference to the anhydrous substance.